Yang Xu | Medicine | Best Researcher Award

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.

Guohua Yang | Genetics | Best Researcher Award

Assoc. Prof. Dr. Guohua Yang | Genetics | Best Researcher Award

Associate professor | Wuhan University | China

Guohua Yang is an Associate Professor at Wuhan University, specializing in medical genetics and genetic diseases. His research focuses on gene mutations, novel diagnostic methods, and drug discovery for hepatocellular carcinoma. As a dedicated scholar, he holds various leadership roles in genetic and medical associations, contributing significantly to the field.

Profile👤

ORCID

Scopus

Strengths for the Awards

  • Strong Research Focus
    • Expertise in gene mutation and genetic diseases, gene diagnosis, and hepatocellular carcinoma.
    • Contribution to cutting-edge molecular mechanisms and drug discovery research.
  • Notable Publications & Impact
    • Published in reputable journals such as BMC Medical Genomics, Naunyn Schmiedebergs Archives of Pharmacology, Carbohydrate Polymers, Frontiers in Genetics, and Oxidative Medicine and Cellular Longevity.
    • Publications demonstrate interdisciplinary research, integrating genetics, pharmacology, and computational biology.
  • Editorial & Professional Leadership
    • Guest editor and editorial board member for Frontiers in Genetics and Spandidos Journal.
    • Holds leadership roles in multiple genetics and medical associations, indicating high recognition in the field.
  • Innovative Research Applications
    • Contributions to cancer research, including targeted therapies and machine learning-based biomarker identification.
    • Research has potential clinical applications, making a significant societal impact.
  • Guohua Yang is a strong candidate for the Best Researcher Award due to his pioneering contributions to medical genetics, leadership in scientific organizations, and high-quality publications. While he possesses impressive academic credentials, addressing funding, patent contributions, and industry collaborations could further strengthen his profile. Nonetheless, his work in hepatocellular carcinoma and gene mutation research makes him a valuable contender.

🎓 Education

Guohua Yang has received extensive training in medical genetics and related disciplines, equipping him with the expertise to explore genetic disorders and innovative treatment approaches. His educational background has laid a strong foundation for his research in genetic mutations, reproductive health, and cancer biology.

🏢 Experience

As an Associate Professor at Wuhan University, Dr. Yang has led numerous studies on gene mutations and their roles in genetic diseases and cancer progression. He has served as a guest editor for Frontiers in Genetics and is an editorial board member for Spandidos Journal and Brain Research. His leadership extends to serving on various committees, such as the Gene Health Branch of Hubei Genetic Society and the Medical Genetics Branch of Hubei Medical Association.

🔬 Research Interests On Genetics

Dr. Yang’s research revolves around:

  • Genetic mutations and their impact on inherited diseases 🧬
  • Development of advanced gene diagnostic methods 🏥
  • Molecular mechanisms and targeted drug discovery for hepatocellular carcinoma 💊

🏆 Awards

Dr. Yang has been recognized for his outstanding contributions to medical genetics and has been nominated for the Best Researcher Award for his pioneering work in genetic disease research and precision medicine.

📚 Publications

Dr. Yang has contributed to several high-impact journals, with research spanning genetic disorders, cancer therapy, and bioinformatics:

  • “Truncated FRMD7 proteins in congenital Nystagmus: novel frameshift mutations and proteasomal pathway implications”
    • Authors: Y. Su, J. Zhang, J. Gao, Y. Li, G. Yang
    • Publication Year: 2024
    • Citations: 0
  • “Lessons from two patients with Prader–Willi syndrome attributed to heterodisomy and isodisomy”
    • Authors: H. Zhou, J. Zhou, S. Xu, G. Yang, K. Wu
    • Publication Year: 2024
    • Citations: 0
  • “Autophagy inhibition mediated by trillin promotes apoptosis in hepatocellular carcinoma cells via activation of mTOR/STAT3 signaling”
    • Authors: G. Zhan, T. Wei, H. Xie, S. Li, G. Yang
    • Publication Year: 2024
    • Citations: 3
  • Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Year: 2025
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang, Finlay Macrae
  • A novel TSC1 frameshift mutation c.1550_1551del causes tuberous sclerosis complex by aberrant splicing and nonsense‐mediated mRNA degradation (NMD) simultaneously in a Chinese family
    • Year: 2020
    • Authors: Cong Qiu, Chengyan Li, Xiaoyun Tong, Luoyang Dai, Wenda Liu, Yulie Xie, Qimei Zhang, Guohua Yang, Tao Li
  • Identification and Interaction Analysis of Significant Genes and MicroRNAs in Pterygium
    • Year: 2019
    • Authors: Siying He, Hui Sun, Yifang Huang, Shiqi Dong, Chen Qiao, Shuai Zhang, Chen Wang, Fang Zheng, Ming Yan, Guohua Yang

🔚 Conclusion

Dr. Guohua Yang has made significant strides in the field of medical genetics, particularly in gene mutation studies and cancer research. His editorial contributions, leadership roles, and groundbreaking research continue to shape the future of genetic diagnostics and targeted therapies.

Dongmei Li | Genetics | Best Researcher Award

Prof. Dongmei Li | Genetics | Best Researcher Award

Professor | University of Rochester | United States

Dr. Dongmei Li is a distinguished professor at the University of Rochester School of Medicine & Dentistry, where she is actively involved in clinical and translational research. She also holds affiliations with the Goergen Institute for Data Science. With expertise spanning biostatistics, public health sciences, and data science, Dr. Li has made significant contributions to advancing health research through statistical modeling and innovative data analysis methods.

Profile

Scopus

Orcid

Strengths for the Awards

  • Academic and Professional Excellence:
    • Dr. Li holds a Ph.D. in Biostatistics and advanced training in biomedical data science, genetics, and public health, making her expertise highly interdisciplinary.
    • Current roles as Professor and Program Director at the University of Rochester underscore her leadership in academia.
  • Diverse Research Contributions:
    • Dr. Li’s research spans clinical and translational sciences, public health, and biostatistics.
    • Extensive mentorship for students and postdocs, with multiple mentees achieving national recognition.
  • Recognition and Honors:
    • Recipient of numerous awards, such as the David P. Byar Young Investigator Travel Award and mentorship-related accolades for students.
    • Multiple travel grants and special merit awards signify her influence in the research community

Education 🎓

Dr. Li’s academic journey began with a BS in Pomology from Laiyang Agricultural College in China, followed by an MS in Biophysics from China Agricultural University. She later pursued advanced training in the United States, earning an MS in Statistics and a PhD in Biostatistics from The Ohio State University. Her academic pursuits reflect a deep commitment to integrating quantitative methods into biological and health research.

Experience 🏫

Dr. Li’s professional career includes faculty appointments at the University of Hawaii at Manoa, where she developed and taught biostatistics courses, and her current role at the University of Rochester. Over the years, she has advanced from assistant to professor, conducting groundbreaking research in statistical methods for health data and mentoring students and early-career researchers.

Research Interests On Genetics 🔍

Dr. Li’s research focuses on applying statistical models to complex health data, including biomarker discovery, tobacco research, and diabetes studies. She is particularly interested in integrating machine learning with traditional biostatistics to address challenges in health disparities and population health. Her interdisciplinary approach bridges the gap between health sciences and computational methods.

Awards 🏆

Dr. Li has been recognized for her contributions to research and mentoring, receiving accolades such as the David P. Byar Young Investigator Travel Award and the National Student Employee of the Year Award for her mentees. Her numerous scholarships and travel awards highlight her dedication to fostering collaborative research and innovation.

Publications 📚

  • “Assessing associations between individual-level social determinants of health and COVID-19 hospitalizations: Investigating racial/ethnic disparities among people living with human immunodeficiency virus (HIV) in the U.S. National COVID Cohort Collaborative (N3C)”
    • Authors: Dimple Vaidya, Kenneth J. Wilkins, Eric Hurwitz, Jessica Y. Islam, Dongmei Li, Jing Sun, Sandra E. Safo, Jennifer M. Ross, Shukri Hassan, Elaine Hill, et al.
    • Publication Year: 2024
    • Citations: As of now, this publication has not been cited by other works.
  • “Public Perceptions of Very Low Nicotine Content on Twitter: Observational Study”
    • Authors: Zidian Xie, Xinyi Liu, Xubin Lou, Dongmei Li
    • Publication Year: 2024
    • Citations: This study has been cited by the following publications:
      • Tracy T. Smith, Richard J. O’Connor, K. Michael Cummings, Alex C. Liber, “Tobacco Control Strategies,” International Encyclopedia of Public Health, 2025.
      • Kiana L. Fall, Robin M. Forbes-Lorman, “No effect on behavior in a pilot study investigating the role of progesterone in nicotine withdrawal in female rats,” BIOS, 2024.
      • Piyush Anand, Vrinda Kadiyali, “Frontiers: Smoke and Mirrors: Impact of E-cigarette Taxes on Underage Social Media Posting,” Marketing Science, 2024.
      • Onyema Greg Chido-Amajuoyi, Dale S. Mantey, Efehi Igbinomwanhia, Onyinye Omega-Njemnobi, Henry Onyeaka, Robert K. Yu, Israel Agaku, Sanjay Shete, “Perceptions of the Addictiveness of Low-Nicotine Cigarettes Versus Typical Cigarettes and Exposure to Tobacco Industry-Sponsored Corrective Campaign,” Substance Use & Misuse, 2024.
      • Carlos Blanco, Benjamin Apelberg, Brian A. King, Wilson M. Compton, “Opportunities for advancing science to inform tobacco regulation in an evolving tobacco landscape,” Molecular Psychiatry, 2024.
  • “Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic”
    • Authors: Lisette Alcantara Sanchez, Eloy Alvarez Guerra, Dongmei Li, Samantha M. King, Shannon P. Hilchey, Qian Zhou, Stephen Dewhurst, Kevin Fiscella, Martin S. Zand
    • Publication Year: 2024
    • Citations: This publication has not been cited by other works to date.
  • “Marker gene fishing for single-cell data with complex heterogeneity”
    • Authors: Yiren Shao, Qi Gao, Liuyang Wang, Dongmei Li, Andrew B. Nixon, Cliburn Chan, Qi-Jing Li, Jichun Xie
    • Publication Year: 2024
    • Citations: Currently, there are no citations for this preprint.
  • “Associations of County-Level Social Determinants of Health with COVID-19 Related Hospitalization Among People with HIV: A Retrospective Analysis of the U.S. National COVID Cohort Collaborative (N3C)”
    • Authors: Jessica Y. Islam, Eric Hurwitz, Dongmei Li, Marlene Camacho-Rivera, Jing Sun, Sandra Safo, Jennifer M. Ross, Kenneth Wilkins, Shukri Hassan, Elaine L. Hill, et al.
    • Publication Year: 2024
    • Citations: This article has not been cited by other publications yet.
  • “Discussion of Heated Tobacco Products on Twitter Following IQOS’s Modified-Risk Tobacco Product Authorization and US Import Ban: Content Analysis”
    • Authors: Minji Kim, Julia Vassey, Dongmei Li, Artur Galimov, Eileen Han, Matthew G. Kirkpatrick, Cassandra A. Stanton, Jenny E. Ozga, Sarah Lee, Jennifer B. Unger
    • Publication Year: 2024
    • Citations: No citations have been recorded for this study so far.
  • “Temporal and Thematic Analysis of Promotional Waterpipe-Related Posts on Twitter/X in the US”
    • Authors: Puhua Ye, Mengwei Wu, Yiwei Han, Yuka Shimazaki, Jennifer Cornacchione Ross, Erin L. Sutfin, Dongmei Li, Zidian Xie
    • Publication Year: 2024
    • Citations: This preprint has not been cited by other works.
  • “Public Perception of the Tobacco 21 Amendment on Twitter in the United States: Observational Study”
    • Authors: Liane M. Schneller-Najm, Zidian Xie, Jiarui Chen, Sarah Lee, Emily Xu, Dongmei Li
    • Publication Year: 2024
    • Citations: There are no citations for this study at this time.
  • “Public Perceptions of the Food and Drug Administration’s Regulatory Authority Over Synthetic Nicotine on Twitter: Observational Study”
    • Authors: Jonathan Zou, Juan Ramon Feliciano, Zidian Xie, Dongmei Li
    • Publication Year: 2024
    • Citations: This publication has not been cited by other works to date.

Conclusion 🌟

Dr. Dongmei Li’s extensive expertise, innovative research, and dedication to mentoring make her a valuable asset to the academic and scientific community. Her work continues to impact the fields of biostatistics and public health, fostering collaboration across disciplines and inspiring the next generation of researchers.

Guoli Li | Medicine | Best Researcher Award

Dr. Guoli Li | Medicine | Best Researcher Award

Researcher | Hunan Provincial People’s Hospital (The First-Affiliated Hospital of Hunan Normal University) | China

Dr. Guoli Li, Ph.D., is an Assistant Professor at Hunan Provincial People’s Hospital and the First Affiliated Hospital of Hunan Normal University, located in Changsha, China. With expertise in Molecular Medicine, Cancer Research, and Nephrology, Dr. Li has contributed extensively to the scientific community, focusing on cutting-edge advancements in medical research.

Profile

Google Scholar

Strengths for the Awards

  • Extensive Research Background:
    Dr. Guoli Li has a strong academic and research foundation in molecular medicine, cancer research, and nephrology, with significant experience at reputable institutions like the University of Texas MD Anderson Cancer Center and Hunan Normal University.
  • Diverse Publication Record:
    Dr. Li has authored numerous high-impact publications in peer-reviewed journals such as Frontiers in Oncology, Genes and Diseases, and BMC Nephrology. These papers cover critical topics like cancer biomarkers, glomerulopathy, and ferroptosis in cancer, demonstrating expertise in innovative and clinically relevant research.
  • Bibliometric Contributions:
    Contributions to bibliometric studies (e.g., research on ferroptosis and mitophagy) highlight Dr. Li’s ability to analyze global research trends, adding to their scholarly influence.

Education 🎓

  • Ph.D. in Biochemistry and Molecular Biology (2013–2017)
    Central South University, Changsha, Hunan, China
  • B.S. in Biotechnology (2008–2012)
    Changchun University of Technology, Changchun, Jilin, China

Experience 💼

  • Research Scientist (09/2020–Present)
    Hunan Provincial People’s Hospital, Hunan Normal University, Changsha, Hunan, China
  • Postdoctoral Fellow (09/2018–08/2020)
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • Instructor (06/2018–06/2020)
    Guangzhou Medical University, Guangzhou, Guangdong, China
  • Technician (08/2012–08/2013)
    Sansure Biotech Inc., Changsha, Hunan, China

Research Interests On Molecular Medicine🔬

Dr. Li’s research spans:

  • Molecular mechanisms in cancer biology 🧬
  • Nephrology, focusing on lupus nephritis and glomerulopathy 🩺
  • Biomarker identification and therapeutic development 🚑

Awards 🏆

  • 2018: Outstanding Graduate
  • 2016-2017: Excellent Graduate Student
  • 2009-2010: Excellent Student and Excellent Student Leader

Publications 📚

  • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing
    Authors: G Li, X Guo, L Tang, M Chen, X Luo, L Peng, X Xu, S Wang, Z Xiao, W Yi, …
    Year: 2017
    Citations: 43
  • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients
    Authors: G Li, X Guo, M Chen, L Tang, H Jiang, JX Day, Y Xie, L Peng, X Xu, J Li, …
    Year: 2018
    Citations: 39
  • What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients
    Authors: W Wang, H Liu, G Li
    Year: 2022
    Citations: 26
  • Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients
    Authors: J Heng, X Guo, W Wu, Y Wang, G Li, M Chen, L Peng, S Wang, L Dai, …
    Year: 2017
    Citations: 20
  • The research landscape of ferroptosis in cancer: a bibliometric analysis
    Authors: G Li, Y Liang, H Yang, W Zhang, T Xie
    Year: 2022
    Citations: 17
  • Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients
    Authors: Y Xie, G Li, M Chen, X Guo, L Tang, X Luo, S Wang, W Yi, L Dai, J Wang
    Year: 2018
    Citations: 16
  • Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients
    Authors: T Xie, M Chen, X Tang, H Yin, X Wang, G Li, J Li, X Zuo, W Zhang
    Year: 2016
    Citations: 16
  • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
    Authors: H Deng, M Chen, X Guo, J Heng, X Xu, L Peng, H Jiang, G Li, JX Day, J Li, …
    Year: 2019
    Citations: 11
  • Bibliometric insights of global research landscape in mitophagy
    Authors: G Li, W Yin, Y Yang, H Yang, Y Chen, Y Liang, W Zhang, T Xie
    Year: 2022
    Citations: 10
  • LINC00467 is upregulated by DNA copy number amplification and hypomethylation and shows ceRNA potential in lung adenocarcinoma
    Authors: W Wang, H Bo, Y Liang, G Li
    Year: 2022
    Citations: 9

Conclusion 📝

Dr. Guoli Li is a passionate scientist and educator committed to advancing medical research and improving clinical outcomes. With numerous prestigious publications, awards, and invitations as a reviewer for reputed journals, Dr. Li continues to contribute profoundly to the global research community. 🌐

Mario Troisi | Medicine | Excellence in Innovation

Dr. Mario Troisi | Medicine | Excellence in Innovation

MD | University of Naples Federico II | Italy

Mario Troisi, MD, is an accomplished ophthalmologist and senior resident at the University of Naples Federico II, Italy. He graduated with distinction from the University of Salerno in Medicine and Surgery (110/110 cum laude). Dr. Troisi specializes in ocular surface diseases and corneal surgeries and has participated in numerous prestigious international fellowships, including a corneal fellowship at the University of Brescia and a cataract surgery program in Egypt. A prolific researcher and speaker, he has presented at over 30 national and international conferences. In 2024, Dr. Troisi received the ESCRS Trainee Bursary and the EVER Andrzej Grzybowski Award, highlighting his outstanding contributions to ophthalmology.

Profile

Orcid

Scopus

Google Scholar

Strengths for the Awards

  • Innovative Research Contributions:
    • Dr. Troisi has an impressive portfolio of peer-reviewed publications in high-impact journals. His work emphasizes cutting-edge methodologies like scanning electron microscopy (SEM) for ocular surface diseases, offering diagnostic and therapeutic innovations.
    • Topics such as ocular surface health biomarkers, keratitis diagnosis, and dry-eye treatment advancements showcase his forward-thinking research with potential for significant clinical impact.
  • Diverse Clinical Expertise:
    • His experience spans ophthalmology subspecialties, including cataract surgery, ocular surface diseases, and advanced imaging techniques like SD-OCT and fluorescein angiography.
    • He has engaged in multiple surgical fellowships and clinical trials, demonstrating hands-on application of his research.
  • Recognition and Awards:
    • Dr. Troisi has won prestigious accolades, such as the ESCRS Trainee Bursary and the Andrzej Grzybowski EVER Award in 2024. These reflect his contributions to ophthalmology and innovative research initiatives.
    • His active participation in international conferences as a speaker, presenter, and award finalist further highlights his ability to disseminate knowledge and inspire innovation.
  • Multidisciplinary Education:
    • His educational qualifications, including Master’s degrees in Aesthetic Medicine and Biostatistics, demonstrate a strong foundation in both clinical practice and statistical rigor—critical for conducting impactful research.

Education 🎓📚

Dr. Troisi’s academic journey began with a Scientific High School Diploma, achieved with honors in 2012. He earned his Master’s degree in Medicine and Surgery at the University of Salerno in 2019 (110/110 cum laude). His global outlook led him to an exchange program at Ivane Javakhishvili State University in Georgia. Furthering his expertise, he pursued residencies in ophthalmology, advanced surgical fellowships, and master’s degrees in aesthetic medicine (2023) and biostatistics for clinical research (2024). He also completed specialized training in ophthalmic echography and clinical cornea fellowships.

Professional Experience 💼

Since 2020, Dr. Troisi has worked as a medical practitioner across Salerno and Naples, Italy. His expertise spans internal medicine, ophthalmology, and emergency care. Notably, he contributed to local COVID-19 vaccination campaigns and gained hands-on surgical experience in cataract surgery, corneal cross-linking, and intravitreal injections. Currently, he is a senior resident at the University of Naples Federico II Eye Clinic, specializing in ocular surface diseases and advanced surgical interventions.

Research Interests On Medicine 🔬

Dr. Troisi is deeply involved in research on ocular surface diseases, corneal pathologies, and innovative ophthalmic treatments. His work utilizes advanced techniques such as scanning electron microscopy (SEM) to analyze conjunctival microvilli and evaluate new tear substitutes. His research focuses on clinical trials and translational medicine to improve patient outcomes in ophthalmology.

Awards and Recognitions 🏆🌟

Dr. Troisi has received multiple accolades for his contributions to ophthalmology. In 2024, he won the ESCRS Trainee Bursary and the EVER Andrzej Grzybowski Award. Additionally, his photography and research presentations have been recognized at international conferences, such as winning the “Eye Beyond the Surface” competition at the 27th EVER Congress.

Publications 📑📘

  • Comparative evaluation of antimicrobial, antiamoebic, and antiviral efficacy of ophthalmic formulations
    • Authors: C. Caruso, D. Eletto, A. Tosco, M. Pannetta, F. Scarinci, M. Troisi, A. Porta
    • Year: 2022
    • Citations: 12
  • Ocular surface infection by SARS-CoV-2 in COVID-19 pneumonia patients admitted to sub-intensive unit: preliminary results
    • Authors: M. Troisi, C. Zannella, S. Troisi, M. De Bernardo, M. Galdiero, G. Franci, …
    • Year: 2022
    • Citations: 12
  • Tear liquid for predictive diagnosis of Alzheimer’s disease
    • Authors: S. Del Prete, D. Marasco, R. Sabetta, A. Del Prete, F. Z. Marino, R. Franco, …
    • Year: 2021
    • Citations: 10
  • Scanning Electron Microscopy of Conjunctival Scraping: Our Experience in the Diagnosis of Infectious Keratitis with Negative Culture Tests
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, C. Costagliola
    • Year: 2023
    • Citations: 5
  • Correlative microscopy (CLEM) of tarsal conjunctival scraping: A new opportunity in the diagnosis of microbial keratitis
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, C. Costagliola
    • Year: 2024
    • Citations: 3
  • Utility of Scanning Electron Microscopy (SEM) for Suspected Microbial Keratoconjunctivitis Unresponsive to Broad-Spectrum Antibiotic Therapy
    • Authors: M. Troisi, S. Del Prete, S. Troisi, M. V. Turco, V. Turco
    • Year: 2023
    • Citations: 3
  • Scanning Electron Microscopy (SEM) Evaluation of the Ultrastructural Effects on Conjunctival Epithelial Cells of a New Multiple-Action Artificial Tear Containing Cross-Linked Hyaluronic Acid
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, M. Rinaldi, C. Costagliola
    • Year: 2024
    • Citations: 2
  • Scanning electron microscopy (SEM) of conjunctival scraping for the diagnosis of atypical cases of Acanthamoeba in culture-negative keratoconjunctivitis
    • Authors: M. Troisi, S. Del Prete, S. Troisi, D. Marasco, C. Costagliola
    • Year: 2024
    • Citations: 2
  • Compatibility of a New Ocular Surface Dye with Disposable and Bi-Weekly Soft Contact Lenses: An Experimental Study
    • Authors: M. Troisi, C. Caruso, L. D’Andrea, M. Rinaldi, R. Piscopo, S. Troisi, …
    • Year: 2024
    • Citations: 2
  • Corneal collagen cross-linking in patients with keratoconus from the Dresden protocol to customized solutions: theoretical basis
    • Authors: C. Caruso, L. D’Andrea, M. Troisi, M. Rinaldi, R. Piscopo, S. Troisi, …
    • Year: 2024
    • Citations: 2

Awards and Presentations🏅

Dr. Troisi has delivered over 30 presentations at esteemed conferences:

  • “SEM Insights into Ocular Surface and Dry Eye Management” – Finalist, Clinical Case Competition, European Dry Eye Society, 2024.
  • “Pathological Alterations of Microvilli Structure” – Winner of the EVER Scientific Photography Competition, 2024.
  • “The Role of Scanning Electron Microscopy in Acanthamoeba Diagnosis” – ESCRS, 2024.

Conclusion 🌍

Dr. Mario Troisi’s dedication to ophthalmology is evident in his clinical expertise, research contributions, and academic achievements. His innovative approach to ocular surface diseases and commitment to advancing medical knowledge position him as a rising leader in the field.